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Abstract
Introduction: Osteoarthritis (OA) is a leading cause of disability, but despite the high unmet clinical need and
extensive research seeking dependable therapeutic interventions, no proven disease-modifying treatment for OA
is currently available. Due to the close interaction and interplay between the articular cartilage and the subchondral
bone plate, it has been hypothesized that antiresorptive drugs can also reduce cartilage degradation, inhibit excessive
turnover of the subchondral bone plate, prevent osteophyte formation, and/or that bone anabolic drugs might also
stimulate cartilage synthesis by chondrocytes and preserve cartilage integrity. The benefit of intensive zoledronate (Zol)
and parathyroid hormone (PTH) therapy for bone and cartilage metabolism was evaluated in a rat model of OA.
Methods: Medial meniscectomy (MM) was used to induce OA in male Lewis rats. Therapy with Zol and human PTH
was initiated immediately after surgery. A dynamic weight-bearing (DWB) system was deployed to evaluate the
weight-bearing capacity of the front and hind legs. At the end of the 10-week study, the rats were euthanized
and the cartilage pathology was evaluated by contrast (Hexabrix)-enhanced μCT imaging and traditional histology. Bone
tissue was evaluated at the tibial metaphysis and epiphysis, including the subchondral bone. Histological techniques and
dynamic histomorphometry were used to evaluate cartilage morphology and bone mineralization.
Results: The results of this study highlight the complex changes in bone metabolism in different bone compartments
influenced by local factors, including inflammation, pain and mechanical loads. Surgery caused severe and extensive
deterioration of the articular cartilage at the medial tibial plateau, as evidenced by contrast-enhanced μCT and
histology. The study results showed the negative impact of MM surgery on the weight-bearing capacity of the
operated limb, which was not corrected by treatment. Although both Zol and PTH improved subchondral bone
mass and Zol reduced serum CTX-II level, both treatments failed to prevent or correct cartilage deterioration,
osteophyte formation and mechanical incapacity.
Conclusions: The various methods utilized in this study showed that aggressive treatment with Zol and PTH did
not have the capacity to prevent or correct the deterioration of the hyaline cartilage, thickening of the subchondral
bone plate, osteophyte formation or the mechanical incapacity of the osteoarthritic knee.
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Introduction
Osteoarthritis (OA) is a complex disease of the entire joint,
affecting the cartilage, bone and synovial membranes [1].
With the aging of the population in the United States, OA,
as the most prevalent form of arthritis, contributes consid-
erably to the economic and social burden on the health
care system [2]. The multifactorial etiology of OA and the
inevitable presence of risk factors such as abnormal load-
ing, obesity, repetitive injuries and aging, which persist
throughout the life cycle of the disease, make treatment ex-
tremely difficult [3]. Clearly, multitherapeutic approaches
over longer durations will be necessary to effectively treat
this debilitating disease. Despite the high unmet need and
extensive research seeking dependable therapeutic inter-
ventions, no proven disease-modifying treatments for OA
are currently available.
The mechanical and metabolic roles of the subchondral
bone are considered critical for the health of the articular
cartilage and for normal joint physiology [4, 5]. Increased
turnover, osteophyte formation and osteosclerosis are the
most common features of subchondral bone pathophysi-
ology that frequently accompany cartilage degradation in
OA patients [5, 6]. Interdependence of articular cartilage
and subchondral bone, in both healthy and diseased states,
led to suggestions to expand the use of drugs approved to
treat osteoporosis (OP) to also treat bone and, subse-
quently, cartilage in OA patients [7–9]. This proposal may
sound controversial since the previous studies seem to
suggest that OA is inversely related to OP and that OA is
associated with increased bone mineral density [10, 11].
However, proposals to use antiresorptive bone therapy to
treat OA is largely based on the premise that this therapy
will reduce cartilage degradation, inhibit excessive turn-
over of the subchondral bone plate and prevent bone loss
in the limb affected by OA [6, 12]. Treatment with bispho-
sphonates has been shown to reduce cartilage degradation
[13–15], have no effect [16, 17], or even to have a negative
effect [18] on articular cartilage in animal models of OA.
Clinical results, however, failed to demonstrate lessening
of symptoms or improvement of radiographic progression
in patients with OA treated with antiresorptive agents
[19, 20]. Parathyroid hormone (PTH), known as teri-
paratide in drug form, has emerged as a major player in
the maintenance and healing of bone, but the literature
discussing usefulness of PTH to treat OA is less indica-
tive [21, 22]. However, sharing of a mesenchymal cell
lineage by osteoblasts and chondrocytes suggests that
treatment with PTH might stimulate cartilage synthesis
by chondrocytes and protect against cartilage degrad-
ation [23–27]. This implies that perhaps immediate and
aggressive treatment with PTH will be more beneficial
to prevent cartilage degeneration and initiate the heal-
ing in patients with posttraumatic OA (PTOA). Overall,
published literature on bone therapies indicates that
carefully selected antiresorptive and anabolic treatment
could provide benefit to a selected patient population
with OA. The data also suggest that aggressive preemptive
antiresorptive therapy might be more effective in inhibit-
ing cartilage degradation and excessive turnover of the
subchondral bone in posttraumatic states [15, 28, 29].
Also, it should be noted that the majority of preclinical
studies utilize intermittent dosing with PTH based on
bone-efficacy data [30], even though the work done by
Kudo and colleagues showed similar efficacy on cartilage
repair with continuous and intermittent administration of
PTH [26].
Damage to the meniscus or ligaments within the knee
caused by trauma or repeated microtrauma are widely
accepted as common causes of PTOA in this joint [27].
A unilateral medial meniscectomy (MM) in rats primar-
ily results in fast and progressive degenerative changes
of the articular cartilage of the medial tibial plateau,
whereas subchondral bone pathology (sclerosis and for-
mation of osteophytes) is deemed secondary and reflects
local adaptation of the skeleton to new mechanical
demands [31–34]. Patients with acute traumatic cartilage
injury will probably benefit the most from prompt and
aggressive therapy that can minimize cartilage damage,
initiate cartilage repair, and prevent secondary changes
of the subchondral bone.
This manuscript reports the outcomes of surgically
imposed meniscal injury on cartilage health and the load-
bearing capacity of the operated limb, and the reaction of
hyaline cartilage and bone to intensive treatment with
antiresorptive (zoledronate) and anabolic bone (PTH)
therapy. Cartilage and bone pathology was evaluated by
using serum biomarkers of bone and cartilage metabolism,
micro-computed tomography (μCT) analysis of cartilage
and bone tissue and cartilage histology.
Methods
Animals and management
Four-month-old male Lewis rats (Charles River Labora-
tories, Portage, MI, USA) weighing approximately 350 g
at the beginning of the experiments were used in this study.
All in vivo procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) at Pfizer
(Andover, MA, USA) and were performed in accord-
ance with the Guide for the Care and Use of Laboratory
Animals and with the US National Institutes of Health
(NIH) Publication No. 85-23, revised in 1996 [35]. All ef-
forts were made to minimize animal pain and distress and
to minimize the number of animals used. The rats were
pair housed in ventilated Innovive cages in a temperature-
and humidity-controlled room on a regular 12-hour light/
dark cycle. Irradiated LabDiet™ 5053 (Purina, Richmond,
IN, USA) and water were provided ad libitum. The rats
were acclimated for 1 week prior to use in the study. A
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total of 48 rats were used for the 10-week study, with 12
rats per group. The rats were randomized to four study
groups based on their body weights on the day before sur-
gery. A group of 12 rats received sham surgery, and
another group of 36 rats underwent MM surgery. The four
study groups were as follows: sham control group (Sham),
MM vehicle-treated group (MM+ veh), MM+ zoledronate
group (MM+Zol) and MM+PTH group (MM+PTH).
Surgery
The rats were induced and maintained under anesthesia
using isoflurane. One dose of carprofen (Pfizer Animal
Health, New York, NY, USA) and sustained-release bupre-
norphine (Zoopharm, Windsor, CO, USA) were adminis-
tered prior to surgery for analgesic coverage. The right
knee was shaved, aseptically prepared, and draped for sur-
gery. In the sham group, a surgical approach to the medial
collateral ligament (MCL) on the right hind limb was
completed by only cutting the skin while the MCL was left
intact. The surgical incision was closed in two layers using
absorbable sutures. In the surgery groups, medial men-
iscectomy (MM) was performed by fully transecting
both the MCL and the medial meniscus of the right
hind limb, followed by closure in two layers using
absorbable sutures [36]. All of the rats were euthanized
at 10 weeks post surgery.
Dosing and bone labeling
The rats in the Sham and MM+ veh control groups
(groups 1 and 2) received vehicle (sterile water used for
injections) at 1 mL/kg subcutaneously (sc) 5 days/week,
starting on the day of surgery. The rats in group 3 received
zoledronic acid (Zol; Sargent Pharmaceuticals 25021-801,
Schaumburg, IL, USA) at 100 μg/kg, sc, twice/week [18],
and the rats in group 4 received human PTH (hPTH 1-34;
Sigma-Aldrich P3796, St. Louis, MO, USA) at 40 μg/kg,
sc, five times/week [25], starting on the day of surgery. To
label actively mineralized bone surfaces, all of the rats in
the study received calcein (Sigma-Aldrich Cat. No. C-0875,
St. Louis, MO, USA) at 10 mg/kg (3.3 mL/kg) 13 days
before necropsy and alizarin (Sigma-Aldrich Cat. No. A-
5533, St. Louis, MO, USA) at 30 mg/kg (3.0 mL/kg) 3 days
before necropsy.
Body weight, sample collection and serum analyses
Body weight was recorded twice weekly throughout the
study. At the end of the 10-week study the entire right
hind limb was carefully harvested, skinned, and cleaned
of the soft tissue, with care taken not to disrupt the knee
joint. The limbs were wrapped in saline-soaked gauze
and frozen at -20 °C for ex vivo imaging and histological
analyses of the tibial articular cartilage and bone. Blood
was collected by jugular venipuncture under isoflurane
anesthesia. Serum was analyzed for biomarkers of bone
formation and bone and cartilage degradation at 5 and
10 weeks post surgery. Osteocalcin was assessed by rat EIA
kit (Cat. No. BT-490, Biomedical Technologies, Stoughton,
MA, USA) and procollagen type 1 N-terminal propeptide
(P1NP) was quantified in serum samples by the liquid
chromatography/mass spectrometry (LC/MS) method
[37]. Cross-linked type I collagen C-terminal telopeptide
(CTX-I) was analyzed by rat LAPS™ Assay (Cat. No. AC-
06 F1) and C-terminal telopeptide of type II collagen
(CTX-II) by CartiLaps™ Assay (Cat. No. AC08F1) all
produced by Immunodiagnostics Systems, Scottsdale,
AZ, USA.
At the end of the study serum chemistry analysis in-
cluded alanine aminotransferase (ALT, U/L), glutamic-
oxaloacetic transaminase (AST, U/L), alkaline phosphatase
(ALP, U/L), gamma-glutamyl transpeptidase (GGT, U/L),
total bilirubin (TBIL, mg/dL), cholesterol (CHOL, mg/dL),
glucose (GLUC, mg/dL), total protein (TP, g/dL), albumin
(ALB, g/dL), globulin (BLOB, g/dL), albumin/globulin ratio
(AG, ratio), blood urea nitrogen (BUN, mg/dL), creatinine
(CREA, mg/dL), phosphorus (PHOS, mg/dL), calcium (Ca,
mg/dL), sodium (Na, mmol/L), potassium (K, mmol/L)
and chloride (Cl, mmol/L).
Dynamic weight bearing
Dynamic weight-bearing (DWB) measurements were
obtained before surgery, at week 5 and before euthanasia
to assess the effects of surgery on the weight-bearing
capacity of the hind and front legs. The DWB system
(model BIO-SWB-R, Bioseb, Boulogne, France) is a non-
invasive method used to obtain the weight and surface
area of all four feet in a freely moving animal [38]. The
system consists of a Plexiglas enclosure (22 × 22 × 30 cm)
with a floor sensor consisting of an array of 44 × 44 sen-
sors. A camera is affixed to the side of the enclosure to
align the sensor directionally during the analysis phase.
Raw pressure and live video recordings are transmitted to
a tablet PC via a USB interface at a sampling frequency of
10 Hz. The data were analyzed using the DWB software,
version 1.3. Zone parameters were set for the analysis as
follows: ≥ 4 g for one sensor or a minimum of three adja-
cent sensors ≥ 2 g (to be considered a valid zone). For each
time segment that was stable for more than 1 second,
zones that met the above criteria were validated and
assigned as either right or left and front or rear. Mean
values for the weight and area of each zone were calculated
over the entire testing period based on the length of time
for each validated segment. For each testing period, the
animals were placed into the chamber and allowed 20–30
seconds to explore prior to the data collection time of
3 minutes. The operator manually “validated” each test
period by ensuring that each paw print corresponded to
the appropriate paw, using the video footage as a refer-
ence. The following parameters were measured for each
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leg separately and for both the front and hind legs com-
bined: body weight (g), weight put on the limb (g), per-
centage of weight placed on the limb and surface area of
each paw (mm2).
Radiology
All of the bone samples were X-rayed with the Faxitron
Model MX20 specimen scanner (Faxitron Bioptics LLC.,
Tucson, AZ, USA) using the settings recommended by the
manufacturer; exposure time 12–18 seconds at 31–35 kV.
All of the samples were imaged at 3× magnification and
were positioned horizontally with the center of the beam
at the knee joint. Both frontal and lateral views of each
sample were obtained. Radiographic images were used to
assess the gross anatomy of the region of interest to be
evaluated by μCT and to inspect the bone samples for the
presence of fractures or other bone abnormalities.
μCT and EPIC μCT measurements
μCT was conducted on the right knee joint, utilizing a
MicroCT 100® computed tomography system (Scanco
Medical, Bassersdorf, Switzerland) to obtain a scout
three-dimensional image of the knee and ensure that the
samples were reproducibly scanned and analyzed exactly
at the same region of interest (ROI) in each specimen
and that the size of the ROI that we selected allowed for
meaningful analysis of bone structures at the proximal
tibial epiphysis and metaphysis.
Following imaging of the entire knee, the femur and
tibia were carefully separated to ensure that the articular
cartilage and meniscus of the joint were not disrupted.
The tibia was then cut above the tibiofibular junction
and the proximal tibia was placed in a plastic custom-
made positioning device to ensure consistent scanning.
Precontrast scans of all the tibias were obtained using
the MicroCT 100® with the following parameters: 800
slices, a 10-μm resolution, a total scanned area of
8.0 mm2, and source energy of 70 kVp, 115 μA at 8 W
to capture the entire proximal tibia section.
Following precontrast μCT scans, 1.2 mL of Hexabrix
(ioxaglate meglumine 39.3 % and ioxaglate sodium
19.6 %; Mallinckrodt, St. Louis, MO, USA) was added to
a 15 mL conical tube and diluted with 1.8 mL of 0.1 M
phosphate-buffered saline containing protease inhibitors
(1 % Protease Inhibitor Cocktail Set I, CalBiochem, San
Diego, CA, USA), yielding a 40 % solution of Hexabrix
[39]. The tibia was then placed in this Hexabrix solution
and was capped and incubated in a covered, rocking
water bath at 37 °C for 3 hours. After the incubation
period, the sample was removed, patted dry and placed
in the plastic positioning device within a μCT holder
containing a small amount of saline to help maintain
sample hydration during scanning. Postsoak scanning of
the right tibia was performed in the same manner as
described above, except that the parameters were set differ-
ently to better visualize the cartilage, with source energy of
55 kVp, 145 μA at 8 W and an average scan time of
42 minutes per sample [39, 40].
μCT evaluation of the cancellous bone at proximal tibial
metaphysis
The cancellous bone compartment of the metaphysis
was analyzed 1 mm below the growth plate and extend-
ing 3 mm distally to include the metaphyseal secondary
spongiosa. Cancellous bone was evaluated in an ROI
drawn on 100 consecutive slices, each 1.0 mm in thick-
ness, which best represented the central segment of the
tibia [41, 42]. Cancellous bone parameters included bone
mineral density (grams of calcium/bone volume), tissue
volume (bone and bone marrow), bone volume, bone
volume/tissue volume ratio, bone surface, bone surface/
bone volume, trabecular number, trabecular thickness,
trabecular separation (distance between individual
trabeculae), connectivity diameter (connection between
individual trabeculae), and structural model index for
shape (Fig. 1a and b).
μCT evaluation of the cancellous bone at proximal tibial
epiphysis
An ROI 2.0 mm× 0.5 mm was drawn on the precontrast
images to include only cancellous subchondral bone under-
lying the articular cartilage. This region was drawn on the
100 consecutive slices (1.0 mm total thickness). Cancellous
bone parameters included bone mineral density (grams of
calcium/bone volume), tissue volume (bone and bone mar-
row), bone volume, bone volume/tissue volume ratio, bone
surface, bone surface/bone volume, trabecular number, tra-
becular thickness, trabecular separation (distance between
individual trabeculae), connectivity diameter (connection
between individual trabeculae), and structural model index
for shape (Fig. 1a and b).
μCT evaluation of the epiphyseal cartilage
Using the postcontrast scans, contour lines were drawn
around an ROI that included the cartilage overlying the
medial tibial plateau. The ROI was purposely drawn to
include a small amount of bone and soft tissue around
the cartilage to ensure that an appropriate threshold was
selected to segment the cartilage from bone tissue and
soft tissue according to histographical analysis of the tis-
sues. After the lower (70) and the upper (440) threshold
was determined, the contour lines were manually drawn
with semiautomatic contouring applied every 3–10 slices
over a total of 300 slices (3 mm) to capture most of the
articular surface (Fig. 1c and d). The three-dimensional
morphology of the entire articular cartilage layer drawn
was then visualized and quantified in terms of average
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cartilage thickness, volume and surface area using direct
distance transformation algorithms [43, 44].
Other ROIs were drawn and analyzed on this central
midpoint of the articular surface, corresponding to
standard histological evaluation techniques for the
articular cartilage [45]. The length of the medial articular
cartilage was measured and divided into three zones of
equal length as already described for the subchondral
bone. The parameters of articular cartilage included car-
tilage volume and cartilage thickness (Fig. 1e and f).
Histology
After the completion of EPIC μCT imaging of the articular
cartilage, six tibias were randomly chosen and placed in
10 % neutral buffered formalin for 72 hours prior to
demineralization for 8 days in Immunocal (Decal Chemical
Corp., Tillman, NY, USA). The tibias were then processed
in paraffin and were serially sectioned at approximately
200 μm intervals into 5 μm-thick sections for staining. The
slides were stained with hematoxylin and eosin (H&E) and
toluidine blue for general structural evaluation and with
safranin O for the evaluation of cartilage damage. Thick-
ness and degeneration of the articular cartilage at the med-
ial tibial plateau were determined on three longitudinal
sections of the proximal tibia using an ocular micrometer.
Cartilage thickness was measured separately on each of
three zones, as suggested in the literature [45–47]. The
severity of OA lesions was graded on a scale adopted from
Osteoarthritis Research Society International (OARSI)
histopathology instructions [45]. Five histological measures
used in this study included damage score, osteophyte size
(μm), significant cartilage degeneration width (μm), cartil-
age thickness (μm) and cartilage matrix loss width (μm).
Undecalcified bones were embedded in methyl meth-
acrylate and were cut into 8 μm-thick longitudinal sections
using a polycut sliding microtome (Leica Biosystems,
Fig. 1 a and b show two-dimensional micro-computed tomography (μCT) images of the proximal tibia from sham control (Sham) (a) and medial
meniscectomy vehicle-treated (MM + veh) rats (b). Red line indicated the area of cancellous bone evaluation at tibial epiphysis (e) and metaphysis
(m). Arrowhead points at the osteophyte. c and d show EPIC μCT images of the same tibias depicted in (a) and (b). The red arrow indicates normal articular
cartilage whereas the dotted arrow indicates osteoarthritic cartilage. e and f show larger EPIC μCT images of the articular cartilage. The length of the medial
tibial plateau was measured for each sample and then divided into three zones ranging from 0.8 to 1.0 mm in length. Zone 1 (Z1) was placed
on the outside of the medial edge of the joint and Zone 3 (Z3) on the inside of the tibial plateau adjacent to the central collateral ligaments.
Zones are delineated by dotted lines. The red arrow indicates normal articular cartilage whereas the dotted arrow indicates
osteoarthritic cartilage
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Nussloch, Germany) or into 20 μm-thick sections using a
bone cutting and grinding system (Exakt Norderstedt,
Germany). The unstained sections were used first to assess
new bone formation at the medial tibial epiphysis, and
these sections were subsequently stained according to Von
Kossa’s method to quantify mineralization.
Statistical analysis
Data are given as means ± standard deviations (SDs).
Differences were tested for significance using three-
factor repeated-measures analysis of variance (ANOVA)
with interactions (Sigma Plot, version 12.2, Systat Soft-
ware, Chicago, IL, USA). Post hoc comparisons of means
with a Bonferroni correction for multiple comparisons
were performed only when interaction effects were sig-




All of the rats enrolled in the study showed similar in-
creases of 15 % in body weight, regardless of treatment. All
of the rats that received the MM surgery developed OA, as
evidenced by μCTand histology. Surgery or treatment with
Zol and PTH did not affect serum chemistry parameters
(data not shown).
Serum biomarkers of bone and cartilage metabolism
After 5 weeks of dosing the MM rats showed higher
CTX-II (p < 0.05) values compared to sham controls.
Zoledronate-treated rats exhibited lower osteocalcin
(p < 0.01), P1NP (p < 0.05) and CTX-II (p < 0.01) relative to
MM controls. On the other hand, rats treated with PTH
exhibited higher osteocalcin (p < 0.01) and lower CTX-II
(p < 0.05) values compared to MM control rats (Table 1).
After 10 weeks of dosing, the MM rats showed higher
CTX-II (p < 0.05) values compared to sham controls.
The rats treated with Zol exhibited lower CTX-II values
(p < 0.05) compared to the MM controls. There was no
difference in serum biomarkers between PTH-treated
rats and MM controls at the end of the10-week study
(Table 1).
Dynamic weight bearing
During the 10 weeks of the study, the weight gain was
similar in all four experimental groups; however, the
MM rats showed a different pattern of weight distribu-
tion compared to the sham controls. The rats tended to
shift their weight forward to their front legs gradually as
they became heavier with age (Fig. 2). In all of the MM
rats, the shift toward the front legs occurred earlier and
was clearly visible at the 5-week time point; therefore,
the weight-bearing load on the front feet in the MM rats
was approximately 20 % greater than in the sham con-
trols (Fig. 2). During the second half of the study, the
sham control rats increased the weight bearing on the
front feet by 34 %, whereas weight bearing in the MM
rats did not change. The load placed on the rear right
leg steadily increased in the sham control rats as they
gained weight during the course of the study, but the
MM rats did not change their load-bearing activity on
the operated limb despite the gain in body weight being
similar between the Sham and MM groups. The weight-
bearing loads placed on the left hind leg were also
increased in MM rats treated with Zol and PTH (Fig. 2).
μCT evaluation of cancellous bone at the tibial
metaphysis
Change in mechanical loading following the MM surgery
resulted in significantly decreased bone volume and tra-
becular number in metaphyseal secondary spongiosa
Table 1 Shows the serum biomarkers of bone and cartilage metabolism at the end of 5 and 10 weeks of the study
5 weeks
Parameter Unit Sham MM+ veh MM + Zol MM + PTH
Osteocalcin ng/mL 32.8 ± 5.0 32.1 ± 5.1 24.3 ± 2.1** 60.4 ± 16.9**
P1NP ng/mL 277.2 ± 73.7 274.8 ± 44.2 243.8 ± 43.8 285.5 ± 44.1
CTX-I ng/mL 22.5 ± 4.4 25.0 ± 5.0 28.9 ± 4.7 30.6 ± 6.3
CTX-II ng/mL 30.5 ± 9.9 39.3 ± 8.7a 13.2 ± 8.5** 30.4 ± 4.0*
10 weeks
Osteocalcin ng/mL 47.1 ± 11.5 38.1 ± 9.3 27.8 ± 11.5 30.7 ± 3.9
P1NP ng/mL 146.0 ± 22.0 174.7 ± 26.1 134.8 ± 29.7 163.7 ± 26.8
CTX-I ng/mL 36.7 ± 3.1 40.5 ± 7.9 49.3 ± 7.6 36.2 ± 4.1
CTX-II ng/mL 14.4 ± 4.1 20.9 ± 5.6a 11.6 ± 3.2* 21.4 ± 5.3
Sham, sham control group, MM + veh medial meniscectomy (MM) vehicle-treated group, MM+ Zol MM+ zoledronate group, MM+ PTH MM + parathyroid hormone
group, P1NP procollagen type 1 N-terminal propeptide, CTX-I cross-linked type I collagen C-terminal telopeptide, CTX-II C-terminal telopeptide of type II collagen
*p < 0.05 or ** < 0.01 relative to MM + veh rats
ap < 0.05 relative to sham rats
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compared to the sham control rats. Treatment with Zol
dramatically improved bone volume, trabecular number
and trabecular thickness compared to the Sham and
MM groups. Treatment with PTH also improved all of
the cancellous bone parameters compared to the Sham
and MM groups (Fig. 3).
μCT evaluation of cancellous bone at the medial tibial
epiphysis
Local change in mechanical loading following the MM
surgery resulted in different morphology of the medial
epiphysis due to thickening of subchondral cortical bone
and formation of osteophytes (Fig. 4). As a result the can-
cellous bone volume was either moderately decreased
(MM+ veh) or increased (MM+Zol and MM+PTH).
Treatment with Zol improved cancellous bone volume
largely through increase in trabecular thickness (p < 0.05).
Trabecular number and trabecular thickness (p < 0.05)
were both increased in PTH-treated rats compared to the
MM+ veh controls (Fig. 4).
EPIC μCT evaluation of the articular cartilage at the
medial tibial plateau
The cartilage volume was significantly greater in Zones
1 and 3 (Z1 and Z3) but was significantly lower in Zone
2 (Z2) in all of the MM rats compared to the sham
controls. The cartilage volume values were similar in
all three groups of MM rats. The cartilage was sig-
nificantly thicker in Z1 in all of the MM rats com-
pared to the controls, but it was considerably thinner
in Z2 in the MM rats compared to the sham con-
trols. The cartilage thicknesses were similar in Z3 in
all of the study groups, although the values were
somewhat smaller in the MM rats than in the con-
trols (Table 2, Fig. 5).
Histology
Histological evaluation of the articular cartilage revealed
classic images of cartilage degradation caused by the MM
surgery, including a thinning to complete absence of the
cartilage due to chondrocyte death or atrophy, cartilage
fibrillation and the presence of osteophytes. In the control
Fig. 2 Changes in the body weight (a) and weight-bearing activity of the front feet (b), rear left leg (c) and on the operated rear right leg (d).
The weight-bearing load on the front feet in all three groups of medial meniscectomy (MM) rats was greater at the 5-week time point compared
to the sham control (Sham) rats. The load on the rear right leg was diminished in all three groups of MM rats at both week 5 and week 10. *p < 0.05
relative to Sham rats
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Fig. 3 Two-dimensional micro-computed tomography (μCT) images of the proximal tibia from rats assign to study group 3A to 3D.
Arrows indicate cancellous bone at the tibial metaphysis. Graph underneath depicts trabecular bone volume (a), trabecular number (b) and
trabecular thickness (c) parameter obtained by μCT at proximal tibial metaphysis of the operated right leg. ap < 0.05 relative to sham
control (Sham) rats; *p < 0.05 or **p < 0.01 relative to medial meniscectomy vehicle-treated (MM + veh) rats
Fig. 4 Two-dimensional micro-computed tomography (μCT) images of the medial tibial epiphysis from rats assign to study group 4A to 4D. Pink
lines indicate area of the cancellous bone assessment. Arrowheads indicate osteophytes; arrows indicate accumulation of subchondral bone. Graph
underneath depicts trabecular bone volume (a), trabecular number (b) and trabecular thickness (c) parameter obtained by μCT at proximal tibial
metaphysis of the operated right leg. ap<0.05 relative to sham control (Sham) rats; *p<0.05 relative to medial meniscectomy vehicle-treated (MM+veh) rats
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rats, the articular cartilage at the medial tibial plateau
grew progressively thicker from the most medial (Z1) to
the most lateral part (Z3), as revealed in histological
sections and scoring (Fig. 6a; 7d). As a result of mech-
anical imbalance caused by the MM surgery, articular
cartilage at the most medial half of Z1 next to the
osteophytes was thickening, whereas the most lateral
half of Z1 became very thin. The cartilage was very thin
and in some cases completely missing in Z2 in the
MM + veh rats, whereas the cartilage thickness in Z3
was comparable between the Sham and MM rats
(Fig. 6b; 7a-d). Treatment with Zol and PTH did not
have significant effects on the thickness of the articular
cartilage or on the formation and size of the osteophytes
(Fig. 6c and d; 7a-d).
Dynamic histomorphometry
Labeling of actively mineralizing bone surfaces with cal-
cein and alizarin red revealed active bone remodeling of
the epiphyseal bone and osteophytes in all of the MM rats.
Treatment with Zol and PTH did not influence the size of
the osteophyte formation; however, bone remodeling was
more active in the epiphysis of Zol- and PTH-treated rats
than in the Sham and MM+ veh controls (Fig. 8).
Discussion
Osteoarthritis is the most common form of arthritis in
the United States and is a leading cause of disability [2, 3].
The incidence and prevalence of OA is rising due to an
aging population and the growing frequency of risk factors
including obesity and genetics, as well as joint-specific
Table 2 Zonal measurement of the cartilage volume and thickness at the medial tibial plateau
S T U D Y G R O U P S
Parameter Unit Zone Sham MM+ veh MM + Zol MM + PTH
z1 0.12 ± 0.02 0.19 ± 0.06
* 0.19 ± 0.06* 0.19 ± 0.06*
Cartilage mm3 z2 0.20 ± 0.02 0.11 ± 0.04
** 0.12 ± 0.03** 0.12 ± 0.06**
Volume z3 0.19 ± 0.04 0.23 ± 0.04
* 0.23 ± 0.05* 0.23 ± 0.06*
z1 0.14 ± 0.02 0.18 ± 0.06
* 0.18 ± 0.04* 0.18 ± 0.07*
Cartilage mm z2 0.23 ± 0.02 0.15 ± 0.04
** 0.15 ± 0.03** 0.15 ± 0.06**
Thickness z3 0.23 ± 0.04 0.20 ± 0.03 0.21 ± 0.03 0.20 ± 0.05
Sham, sham control group, MM + veh medial meniscectomy (MM) vehicle-treated group, MM+ Zol MM+ zoledronate group, MM+ PTH MM + parathyroid
hormone group
*p < 0.05 or **p < 0.001 relative to sham rats
Fig. 5 Top row shows EPIC micro-computed tomography (μCT) images of the articular cartilage covering the medial tibial plateau from rats
assign to study group 5A to 5D. Arrows indicate cartilage defects present in all three groups of operated rats. Second row depicts large cartilage
defects extending over the lateral half of Zone 1 and medial half of Zone 2, as indicated by arrows in three-dimensional μCT color thickness
(“heat”) map of the articular cartilage at the medial tibial plateau
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Fig. 6 Polarized light picture of the proximal tibial epiphysis stained with hematoxylin and eosin (H&E) from rats assign to study group 6A to 6D.
All three groups of medial meniscectomy (MM) rats had thicker subchondral bone plate (sbp), particularly the rats treated with zoledronate (Zol).
Additionally, the calcified cartilage layer seemed to be better preserved in the Zol-treated group. The arrowhead indicates defects of the articular
cartilage, and the green arrowhead indicates osteophytes
Fig. 7 The grading of osteoarthritis (OA) lesions using damage score (a), significant cartilage degeneration width (b), osteophyte size (c), cartilage
thickness (d), and cartilage matrix loss width (e). **Significantly different from sham control group (Sham) at p < 0.01
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factors that are likely reflective of abnormal loading of the
joints [48, 49]. In studying OA, several methodological
challenges exist that can hamper our ability to identify
pertinent relationships. OA is typically defined by radio-
graphic findings and concurrent symptoms.
Modes of locomotion and limb use differ among species
[50, 51], but the ability of the mammalian skeleton to adapt
to mechanical needs has long been recognized and has
been demonstrated in a variety of experimental models
[52–55]. In contrast to bipeds, which can only shift body
weight loads to contralateral limbs, quadrupeds have the
capacity to transfer and disperse loads between the front
and hind legs. The DWB data from this study revealed that
the sham control rats steadily increased body weight loads
on the front and rear legs in proportion to age-related
weight gain. Joint instability and associated pain prevented
Fig. 8 Ultraviolet (UV) images of the medial tibial epiphysis. There is little bone formation in the epiphysis of the sham control (Sham) (a) rat and
more intensive bone formation and buildup of the subchondral bone and osteophyte formation (arrow) in the epiphysis of the medial meniscectomy
vehicle-treated (MM + veh) rat (b). Intensive formation of subchondral bone plate and osteophyte formation is seen in the MM + zoledronic
acid (Zol)- (c) and MM + parathyroid hormone (PTH)-treated rats (d); however, more intensive labeling with both alizarin red and osteocalcin is
evident in the PTH-treated rats. The arrowheads indicate osteophyte formation; e – epiphysis; m – metaphysis; gp – growth plate
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the MM rats from increasing the weight-bearing load on
the operated right leg; instead, the shift in weight load to-
ward the front legs occurred much earlier in the MM rats
than in the sham controls. Although the physical activity
of laboratory rats is rather limited, shifts in weight bearing
toward the front legs and deloading of the right hind leg in
MM rats are likely natural attempts of injured animals to
prevent further joint damage and to reduce pain. There-
fore, similar to the disabilities observed in OA patients, the
pain associated with cartilage and bone pathology in MM
rats resulted in an inability of the injured leg to perform
routine mechanical functions. As a consequence of
reduced weight bearing, the MM control rats showed a
loss of cancellous bone at the proximal tibial metaphysis in
the operated leg. Aggressive treatment with Zol and PTH
resulted in significant gains in cancellous bone by increas-
ing both the trabecular number and trabecular thickness,
albeit via different mechanisms [56, 57], but both treat-
ments failed to improve the weight-bearing capacity of the
operated right leg in the MM rats.
Clinical studies in OA patients have shown limited
diagnostic and prognostic value of bone turnover bio-
markers [58, 59]. The stages of the disease and assay
variability limit the wider use of biomarkers, although
combinations of several biomarkers seem to improve
their prognostic value in clinical use [60, 61]. Although
both sham control and MM rats showed an increase in
osteocalcin and CTX-I and decrease in P1NP and CTX-II
between week 5 and week 10, elevated CTX-II values indi-
cate higher cartilage degradation in MM rats relative to
sham controls. Observed decrease in bone formation
(osteocalcin, P1NP) and cartilage degradation (CTX-II)
was quite expected in Zol-treated rats [14, 62–65], how-
ever, the lack of effect on bone resorption marker CTX-I
was rather unexpected, in particular since the high dose of
Zol was used and histomorphometry and μCT data
showed clear gain in bone mass and accumulation of pri-
mary spongiosa in the metaphyses of Zol-treated rats. Bone
resorption and cartilage degradation biomarkers seem to
be correlated strongly in OA patients, although the origin
of CTX-II has been questioned [66–68]. In PTH-treated
rats there was an increase in serum osteocalcin (p < 0.01)
and P1NP, and decrease in CTX-II values at the 5-week
time point, but at the end of study serum biomarkers in
PTH and MM groups were similar. Again, based on histo-
morphometry and μCT data we expected to see an
increase in P1NP and perhaps osteocalcin throughout the
study, or eventually to see an increase in bone turnover
due to the high and continuous dosing with PTH.
Interpretation of changes in serum biomarkers over
time is not always easy, particularly in rats, due to the
ongoing modeling and remodeling of bone and cartilage
[69, 70]. Clearly, some degree of discrepancy between
serum biomarker data and μCT and histology findings is
to be expected because serum biomarkers reflect the
bone or cartilage metabolism of the entire skeleton for
the particular time point when the serum was collected,
whereas the focus of imaging is the very precise site of
the cartilage and bone lesion that accumulates over a
period of time. This difference is particularly evident in
OA because different parts of the skeleton or even dif-
ferent areas within the same bone experience reverse
metabolism, e.g., subchondral bone undergoes osteosclero-
sis and forms osteophytes while cancellous bone at the
metaphysis is being resorbed. Similarly, articular cartilage
around osteophytes in Zone 1 experience hypertrophy,
while the cartilage in the Zone 2 is undergoing degrad-
ation. The biomarker results from this study support the
notion of Karsdal and colleagues [71], who suggested that
the interpretation of biomarkers is not always straightfor-
ward because several variables, including technical issues
with assays, the stage of the disease and the treatment
paradigm, can influence the significance of the data.
The subchondral bone consists of the subchondral
bone plate (cortical layer) and the subarticular spongiosa
(trabecular bone) and is separated from the calcified
zone of the articular cartilage by the cement line [4, 5].
The articular cartilage and subchondral bone plate ex-
hibit considerable topographical variations in thickness,
density, biochemical composition and vascularity as a
consequence of the different mechanical loads that exist
within the same joint. Greater bone density and strength
are regularly found in the more heavily loaded regions of
the joint surface [72–74]. It was postulated, therefore,
that thicker articular cartilage is needed in the regions of
the joint with low congruency to deform, absorb and
distribute more easily the load-bearing stress on the sub-
chondral bone [75, 76]. The thickening of the articular
cartilage in the most medial part of Zone 1 observed in
the MMT rats certainly supported this notion. Conse-
quently, the subchondral bone must be sufficiently
strong to absorb and further distribute weight-bearing
loads, yet it must contain marrow space, blood vessels and
nerves to enable bone remodeling and to supply nutrients
and oxygen to the subchondral bone plate and calcified
cartilage [75, 77–79]. Eventually, the subchondral bone
plate becomes too thick or sclerotic with the progression
of OA, and when the subchondral bone plate becomes ex-
posed after the complete loss of the articular cartilage, the
chondrocytes in the calcified cartilage become dependent
on the perfusion of the synovial fluid as the only source of
oxygen and nutrients [80]. Unwarranted thickening of the
subchondral bone could also impact the mineralization
front called “tidemark” to fulfill its biomechanical role
when transferring loads from uncalcified cartilage to calci-
fied cartilage and the subchondral bone plate [81, 82].
Due to the close interaction and interplay between the ar-
ticular cartilage and subchondral bone plate, it is reasonable
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to hypothesize that antiresorptive drugs might also reduce
cartilage degradation, inhibit excessive turnover of the sub-
chondral bone [14–18] and prevent osteophyte formation
[14, 62], or that bone anabolic drugs could also stimulate
cartilage synthesis by chondrocytes, preserving cartilage
integrity [25–27] useful in treating OA. The results of our
study clearly show that partial disuse of the operated limb
resulted in mild loss of trabecular bone at the metaphysis
and epiphysis of the proximal tibia, and that both Zol and
PTH possess the capacity to prevent cancellous bone loss
and even cause an increase in trabecular thickness at both
tibial sites despite reduced usage of the injured limb. How-
ever, both tested therapies failed to reduce increased
remodeling of the subchondral bone and formation of the
osteophytes as documented by μCT and histomorphome-
try, or to prevent degradation of the articular cartilage as
evidenced by EPIC μCTand histology.
It was previously suggested that osteoclast-mediated
resorption of mineralized cartilage at the subchondral
bone-cartilage interface is an early initiating event in OA
pathophysiology and that only early bisphosphonate use
after OA induction could result in the observed positive
effect on cartilage health [28]. Although the rats used in
our study received early and aggressive treatment with
Zol, the sole antiresorptive therapy failed to prevent cartil-
age deterioration and osteophyte formation as proposed by
others [13–15, 62]. Our results, however, are in agreement
with clinical results showing that antiresorptive therapy
decreased biomarkers of cartilage degradation but did not
decrease the symptoms or slow the radiographic progres-
sion of OA [19, 83]. Our data also emphasize that the pri-
mary functional determinant of bone architecture is
derived from the bone cells’ adaptive responses to their
recent loading history. Thus within the same bone, differ-
ent bone compartments can experience modeling-driven
bone formation (osteophyte formation), thickening of the
subchondral bone due to increased bone formation and
increased transmitted force on to the underlying bone, or
bone loss at the metaphysis due to disuse of the injured
limb.
In surgical models of OA that mimic the development
of posttraumatic OA, the cartilage damage caused by the
surgery precedes changes in the subchondral bone. It is
thus readily understandable that cartilage damage and
pain lead to mechanical imbalances caused by weight
shifting, incongruent joint surfaces and disuse causing
changes (thickening) to the subchondral bone plate and
osteophyte formation. Therefore, it should be borne in
mind that although surgical preclinical models are good
models for posttraumatic OA, they do not necessarily rep-
resent the more complex etiology of OA occurring in
humans. Translational research, including animal models
and biomarkers, is a critical step toward understanding
and mitigating the long-term effects of the disease process
as well as developing therapeutic interventions that would
likely target various mechanisms to reduce joint inflam-
mation, improve cartilage regeneration and recovery, curb
bone remodeling, reduce disuse caused by pain and im-
prove joint flexibility and recovery.
Conclusions
The various methods utilized in this study showed that
aggressive treatment with Zol and PTH does not have the
capacity to prevent or correct the deterioration of the hya-
line cartilage, thickening of the subchondral bone plate,
osteophyte formation and mechanical incapacity of the
osteoarthritic knee. It seems unlikely that a single drug
will have the capacity to reduce joint inflammation, curb
excessive bone remodeling, improve cartilage regeneration
and reduce pain and that a multitherapeutic approach is
warranted to treat posttraumatic OA.
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